TORONTO, May 7, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that
President Chris Naprawa will present
live at Canaccord Genuity's 4th Annual Global
Cannabis Virtual Conference on Tuesday, May
12, 2020 at 11:40am ET
(8:40am PT).
Canaccord Genuity's Annual Global Cannabis Conference is an
investor-focused virtual event that engages a global network of
leading players in the cannabis industry. To join the presentation
from Mr. Naprawa visit: http://wsw.com/webcast/canaccord39/khrn
Recent Khiron Highlights
- Receives first medical cannabis prescriptions for UK patients
participating in Project Twenty21, Europe's largest study of the effectiveness
and tolerability of medical cannabis
- Signs exclusive agreement with Medlive, a distributor serving
3,000 clinics and hospitals in Brazil, country that represents the largest
addressable market in Latin
America with a population of approximately 212 million
- Signs Medical Cannabis Distribution Deal in Colombia With Locatel, a pharmacy, healthcare
products, and medical equipment retailer with a database of over 2
million patients in Colombia.
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is the dominant integrated medical cannabis company in
Latin America. Khiron has core
operations in Latin America, along
with activity in North America and
Europe, and is licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, has the
first approved line of CBD cosmetic products on shelf
in Colombia, and is fully authorized to manufacture high- and
low-THC medical cannabis, and to fill prescriptions for low-THC
medical cannabis in the country.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-to-present-at-canaccord-genuitys-global-cannabis-virtual-conference-301055248.html
SOURCE Khiron Life Sciences Corp.